Abstract: A process for the preparation of Brivaracetam, an anti-convulsion drug, is provided comprising enzymatic conversion of (2RS)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butyric acid methyl ester selectively into (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butyric acid having high chiral purity, using protease from Bacillus licheniformis. Converting the chirally pure acid into amide results in Brivaracetam.

Abstract: Use of cosmetic and/or dermatological preparations in the form of emulsions, comprising a) an effective amount of one or more ?-hydroxycarboxylic acids and/or an effective amount of one or more ?-hydroxycarboxylic acids b) one or more interface-active substances, chosen from the group of glucose derivatives and, if desired, furthermore comprising (c) one or more interface-active substances chosen from the group of oligoglycerides against blemished skin or acne.

Abstract: Organopolysiloxane gel products having a variety of physical forms and which produce a silky feel when applied to the skin are prepared by reacting an unsaturated organopolysiloxane resin, an Si—H functional organosiloxane crosslinker bearing pendant hydrido functionality, a C4 or higher unsaturated hydrocarbon, and optionally, an unsaturated hydrophile component. Products ranging from viscous liquids, creamy gels, pastes, and soft powders may be obtained. The products are highly useful in formulating cosmetic and pharmaceutical products.

Abstract: The invention described herein encompasses methods of preventing or treating disorders caused by oxidative damage by an aging-specific isoform of NADH oxidase (AR-NOX). The invention encompasses methods of assaying, screening, and identifying agents that inhibit AR-NOX, as well as methods using ubiquinone to inhibit the ability of AR-NOX to generate reactive oxygen species. These agents may be formulated into pharmaceutical compositions in the prevention and treatment of disorders caused by oxidative damage.

Abstract: Free-flowing granular dispersing agents for use in water-dispersible granule (WDG) agricultural chemical formulations are a composite substance comprised of an alkyl polyglycoside and a polymeric anionic dispersant. The granular composite dispersing agents can be used in granular or liquid agricultural chemical formulations, exhibit outstanding attrition resistance, excellent dispersional stability after accelerated aging and low moisture content when made into a paste. The composite dispersing agents are useful as primary dispersants in dry agricultural formulations (wettable powders and water-dispersible granules) and in aqueous suspension concentrates.

Abstract: The invention concerns a topical composition comprising an emulsion of at least one discontinuous phase in a continuous phase, the or each discontinuous phase including a eutectic mixture of first and second pharmaceutically acceptable components which are both pharmacologically active agents and the continuous phase being provided by a pharmaceutically acceptable carrier, the eutectic mixture having a melting point below 40° C. The topical composition may additionally comprise, in the eutectic mixture, a third or fourth pharmaceutically acceptable component.

Abstract: Described in the present invention are a dispersion which comprises, as a dispersoid, (a) 5 to 40 wt. % of an amphipatic lipid containing, in the molecule thereof, at least one hydroxy and amide group, and (b) 2 to 55 wt. % of a surfactant in an aqueous medium; a washing-away type cosmetic composition comprising the dispersion; and a washing-away type cosmetic composition comprising (A) 0.01 to 10 wt. % of an amphipatic lipid which contains, in the molecule thereof, at least one hydroxy and amide group and having a melting point not less than 30° C. and (B) 5 to 95 wt. % of a surfactant. The dispersion according to the present invention is useful as a component of a washing-away type cosmetic composition having both an emulsion-like or pearl-lustrous appearance and low skin irritation.

Abstract: An aqueous stable foam, suitable for use as a vaginal or hemorrhoidal wipe agent, containing at least one surfactant and at least one foam stabilizing agent can be dispensed to bathroom tissue or the like for application to the vaginal or anal area.

Abstract: The invention relates to the cosmetic use of block ethylenic copolymers of elastic nature comprising at least one rigid block having a glass transition temperature (Tg) of greater than or equal to 20° C. and at least one flexible block having a glass transition temperature (Tg) which is less than 20° C., said compolymers making it possible to obtain a film having an instantaneous recovery of between 5% and 100%. The invention also relates to cosmetic compositions containing these block ethylenic polymers of elastic nature.

Abstract: A topical composition containing an aqueous gel which contains a hydrophilic gelling material, wherein the gel has at least one of the following properties: an initial viscosity V0 ranging from 3000 to 50,000 Pa.s, wherein the initial viscosity is stable up to a shear strain C1, a viscosity V2 after shear at a strain C2, wherein a ratio of V0/V2 is greater than or equal to 1000, and a difference of C2-C1 is less than or equal to 100 Pa.

Abstract: A composition containing an emulsifier component having: (a) a hydroxycarboxylic acid alkyl and/or alkenyl oligoglycoside ester; and (b) a fatty alcohol.

Abstract: Water-in-oil emulsions (a) with a content of water and optionally water-soluble substances totalling at least 75% by weight, and with a content of lipids, emulsifiers and lipophilic constituents totalling at most 25%, preferably at most 20%, based in each case on the total weight of the preparations, (b) whose oil phase is chosen from the group of lipids or lipid mixtures, where the total polarity of the lipid phase is between 20 and 30 mN/m, (c) comprising at least one interface-active substance, chosen from the group of alkylmethicone copolyols and/or alkyldimethicone copolyols, (d) optionally, but particularly when the content of water and water-soluble (hydrophilic) constituents is between 75 and 80% by weight, comprising one or more cationic polymers.

Abstract: The invention concerns cosmetic and/or pharmaceutical and/or dermatological compositions and methods for preparing them. The composition is characterized in that it comprises a mixture called base mixture, consisting of a liquid extracted from a mixture (M) of tomatoes and apples once the spontaneous chemical reaction initiated by the mixture of the two crushed plants is completed. The invention is applicable to skin care.

Abstract: The present invention describes rapid noninvasive methods for measuring vasodilation or changes in blood flow in a patient following administration of at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The method comprises the administration of at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent to the patient followed by monitoring the temperature change of an area of interest using infrared thermography.

Abstract: Cosmetic skin care method based on the application to the skin of a combination of the South pole of a static magnet and a cosmetic composition. Also disclosed is a cosmetic dual patch comprising a static magnet layer and a non-woven, transdermal, hydrogel or silicone sheeting patch carrying a cosmetic benefit ingredient wherein the two layers are adhesively bound to each other.

Abstract: A formulation of delta-9-tetrahydrocannabinol in a semi-aqueous solvent, such as 35:10:55 alcohol:water:propylene glycol (v/v), produces a stable clear solution near the solubility point of the drug. Because delta-9-tetrahydrocannabinol has poor affinity for the formulation, it is able to partition out and transport across cell membranes to reach the bloodstream quickly. This has been demonstrated by the comparative tmax values achieved in single dose intravenous and 14 day multiple dose inhalation studies conducted in dogs and rats.

Abstract: A composition, in particular a cosmetic composition, comprising, in an appropriate medium, at least one polymer with a highly specific ordered structure is disclosed. These compositions find a specific application in the field of make-up and are capable of being applied to the skin, semi-mucous membranes and/or mucous membranes. In particular, these compositions can be provided in the form of a transfer-free make-up composition.

Abstract: A method of treating a female suffering from FSD, in particular FSAD, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.

Abstract: A process for preparing a sterile injectable suspension of radiolabeled macroaggregated serum albumin suitable for use in scanning a mammalian patient consisting of: 1) purifying serum albumin with a saline solution; 2) buffering the purified serum albumin; 3) adding stannous halide in HCl solution to the buffered mixture to obtain a reaction mixture; 4) gradually heating and cooling the reaction mixture to form macroaggregate particles; 5) separating the macroaggregates from the reaction mixture; 6) suspending the macroaggregates in sterile water for injection; 7) adding purified serum albumin; 8) lyophilizing the suspension; and 9) reconstituting the radiolabeled lyophilizate with 99mTc. The invention also includes a process for preparing a stable, sterile lyophilizate of macroaggregate particles of human serum albumin consisting of steps 1-7.

Abstract: The invention provides a method of identifying a compound that alters vigilance. The method consists of contacting an invertebrate with a candidate compound, evaluating a vigilance property in the contacted invertebrate, and determining if the candidate compound alters the vigilance property in the contacted invertebrate. A candidate compound that alters the vigilance property in the contacted invertebrate is identified as a compound that alters vigilance. The invention also provides a method of identifying a vigilance enhancing compound that modulates homeostatic regulation or a vigilance diminishing compound that modulates homeostatic regulation. The method consists of contacting an invertebrate with a compound that increases or decreases vigilance, and determining the effect of the compound on a homeostatic regulatory property of vigilance.